دورية أكاديمية
أعرض في EDS

Impact of Epithelial-Mesenchymal Transition on the Immune Landscape in Breast Cancer.

التفاصيل البيبلوغرافية
العنوان: Impact of Epithelial-Mesenchymal Transition on the Immune Landscape in Breast Cancer.
المؤلفون: Khadri FZ; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC H3T 1J4, Canada.; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada., Issac MSM; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC H3T 1J4, Canada.; Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo 11956, Egypt., Gaboury LA; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC H3T 1J4, Canada.; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
المصدر: Cancers [Cancers (Basel)] 2021 Oct 12; Vol. 13 (20). Date of Electronic Publication: 2021 Oct 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: The impact of epithelial-mesenchymal transition (EMT) signature on the immune infiltrate present in the breast cancer tumor microenvironment (TME) is still poorly understood. Since there is mounting interest in the use of immunotherapy for the treatment of subsets of breast cancer patients, it is of major importance to understand the fundamental tumor characteristics which dictate the inter-tumor heterogeneity in immune landscapes. We aimed to assess the impact of EMT-related markers on the nature and magnitude of the inflammatory infiltrate present in breast cancer TME and their association with the clinicopathological parameters. Tissue microarrays were constructed from 144 formalin-fixed paraffin-embedded invasive breast cancer tumor samples. The protein expression patterns of Snail, Twist, ZEB1, N-cadherin, Vimentin, GRHL2, E-cadherin, and EpCAM were examined by immunohistochemistry (IHC). The inflammatory infiltrate in the TME was assessed semi-quantitatively on hematoxylin and eosin (H&E)-stained whole sections and was characterized using IHC. The inflammatory infiltrate was more intense in poorly differentiated carcinomas and triple-negative carcinomas in which the expression of E-cadherin and GRHL2 was reduced, while EpCAM was overexpressed. Most EMT-related markers correlated with plasma cell infiltration of the TME. Taken together, our findings reveal that the EMT signature might impact the immune response in the TME.
References: Cancers (Basel). 2020 Apr 08;12(4):. (PMID: 32276404)
Breast Cancer Res. 2019 May 17;21(1):65. (PMID: 31101122)
Clin Cancer Res. 2014 Dec 1;20(23):5995-6005. (PMID: 25255793)
Oncogene. 2014 Oct 9;33(41):4904-15. (PMID: 24141784)
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7. (PMID: 21908711)
Biomed Pharmacother. 2019 Feb;110:400-408. (PMID: 30530042)
Br J Cancer. 2017 Aug 8;117(4):451-460. (PMID: 28704840)
Front Immunol. 2018 Mar 08;9:470. (PMID: 29568299)
Am J Pathol. 2018 Aug;188(8):1910-1920. (PMID: 29879416)
Oncogene. 2002 May 9;21(20):3241-6. (PMID: 12082640)
Indian J Pathol Microbiol. 2020 Jan-Mar;63(1):13-18. (PMID: 32031116)
Br J Cancer. 2013 Apr 16;108(7):1480-7. (PMID: 23519058)
Indian J Cancer. 2013 Jul-Sep;50(3):189-94. (PMID: 24061457)
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135. (PMID: 30049748)
Pharmacol Ther. 2015 Dec;156:90-101. (PMID: 26388292)
Biomed Pharmacother. 2021 Jan;133:111068. (PMID: 33378968)
BMC Cancer. 2018 Oct 1;18(1):939. (PMID: 30285678)
PLoS One. 2014 Jan 27;9(1):e87377. (PMID: 24475282)
Cell Death Dis. 2020 Feb 24;11(2):147. (PMID: 32094334)
Oncogene. 2017 Jun 29;36(26):3706-3717. (PMID: 28192403)
J Clin Med. 2016 Jan 26;5(2):. (PMID: 26821054)
Nat Med. 1998 Jul;4(7):844-7. (PMID: 9662379)
Nat Commun. 2014 Oct 28;5:5241. (PMID: 25348003)
J Clin Invest. 2019 Apr 1;129(4):1785-1800. (PMID: 30753167)
Oncogene. 2004 Jul 29;23(34):5748-58. (PMID: 15195135)
Ann Oncol. 2013 Sep;24(9):2206-23. (PMID: 23917950)
Nat Med. 2013 Nov;19(11):1423-37. (PMID: 24202395)
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7353-7362. (PMID: 30910979)
Am J Clin Pathol. 1996 Apr;105(4):394-402. (PMID: 8604681)
Front Immunol. 2021 Dec 15;12:797261. (PMID: 34975907)
J Immunother Cancer. 2016 Oct 18;4:59. (PMID: 27777769)
Breast Cancer Res Treat. 2019 Apr;174(3):649-659. (PMID: 30610490)
PLoS One. 2012;7(12):e50781. (PMID: 23284647)
J Clin Pathol. 2011 May;64(5):415-20. (PMID: 21415054)
Cancer Res. 2017 Aug 1;77(15):3982-3989. (PMID: 28428275)
Cancer Discov. 2011 Jun;1(1):54-67. (PMID: 22039576)
EMBO J. 2017 Nov 15;36(22):3336-3355. (PMID: 29038174)
Mod Pathol. 2016 Oct;29(10):1155-64. (PMID: 27363491)
Dev Cell. 2018 Jun 18;45(6):681-695.e4. (PMID: 29920274)
Nat Med. 2018 May;24(5):541-550. (PMID: 29686425)
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. (PMID: 24556840)
Cell Res. 2012 Jan;22(1):90-106. (PMID: 21876555)
Clin Dev Immunol. 2012;2012:890178. (PMID: 22400040)
Ann Oncol. 2012 Sep;23 Suppl 10:x207-10. (PMID: 22987963)
Cancer Res. 2013 Oct 15;73(20):6299-309. (PMID: 23943797)
J Histochem Cytochem. 2020 Jan;68(1):25-32. (PMID: 31787032)
Cell Stem Cell. 2019 Jan 3;24(1):65-78. (PMID: 30554963)
Front Immunol. 2015 Mar 26;6:127. (PMID: 25859247)
Front Immunol. 2018 May 30;9:1209. (PMID: 29899747)
Cancer Res. 2004 Aug 15;64(16):5818-24. (PMID: 15313925)
Nature. 2015 Nov 26;527(7579):472-6. (PMID: 26560033)
Breast Cancer Res. 2001;3(5):289-93. (PMID: 11597316)
Breast Cancer Res. 2019 Dec 26;21(1):151. (PMID: 31878981)
Am J Transl Res. 2014 Nov 22;6(6):793-808. (PMID: 25628790)
J Clin Med. 2019 May 09;8(5):. (PMID: 31075939)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
Int J Oncol. 2001 Mar;18(3):513-20. (PMID: 11179480)
Clinics (Sao Paulo). 2011;66(10):1765-71. (PMID: 22012049)
J Cancer Res Ther. 2017;13(4):707-714. (PMID: 28901319)
Cold Spring Harb Perspect Med. 2020 Jul 1;10(7):. (PMID: 31570380)
Surg Oncol. 2018 Jun;27(2):314-320. (PMID: 29937187)
Exp Cell Res. 2003 Apr 15;285(1):50-8. (PMID: 12681286)
Oncogenesis. 2018 Mar 29;7(3):32. (PMID: 29593211)
Am J Clin Pathol. 2001 Jan;115(1):85-98. (PMID: 11190811)
Immunity. 2018 Mar 20;48(3):399-416. (PMID: 29562192)
NAR Cancer. 2021 Jul 09;3(3):zcab027. (PMID: 34316714)
Oncogene. 2007 Jun 14;26(28):4106-14. (PMID: 17237823)
Curr Cancer Drug Targets. 2013 Nov;13(9):963-972. (PMID: 24168186)
World J Clin Cases. 2017 Jan 16;5(1):1-8. (PMID: 28138440)
Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611. (PMID: 23253225)
Mol Cancer. 2019 May 24;18(1):101. (PMID: 31126310)
Nat Rev Cancer. 2018 Aug;18(8):485-499. (PMID: 29703913)
Cell. 2016 Jun 30;166(1):21-45. (PMID: 27368099)
Mol Oncol. 2017 Jul;11(7):824-846. (PMID: 28614624)
Open Access Maced J Med Sci. 2018 Jun 06;6(6):961-967. (PMID: 29983785)
J Pathol. 2014 Nov;234(3):410-22. (PMID: 25081610)
J Cell Sci. 2002 Nov 1;115(Pt 21):3977-8. (PMID: 12356903)
Exp Cell Res. 1999 Jan 10;246(1):108-21. (PMID: 9882520)
معلومات مُعتمدة: 0 This research was funded by Internal Research funds, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal
فهرسة مساهمة: Keywords: biomarkers; breast cancer; epithelial–mesenchymal transition (EMT); immune landscape; immunohistochemistry; inflammatory infiltrate; protein expression; tumor microenvironment (TME)
تواريخ الأحداث: Date Created: 20211023 Latest Revision: 20240403
رمز التحديث: 20240403
مُعرف محوري في PubMed: PMC8533811
DOI: 10.3390/cancers13205099
PMID: 34680248
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13205099